Express News | Dongcheng Pharmaceutical: Subsidiary Lan Nacheng has resubmitted its application for an H-share listing.

BreakingsJun 15 19:50

Dongcheng Pharmaceutical (002675.SZ): Nuclear Medicine Production Center in Changchun, Jilin Commences Operations

Dongcheng Pharmaceutical (002675.SZ) announced that the company recently received a notice from its wholly owned subsidiary, Nanjing Jiangyuan Andi Ke Positron Research & Development Co., Ltd. (hereinafter referred to as "Andi Ke"), informing it that Andi Ke has obtained a Radioactive Pharmaceutical Production License issued by the Jiangsu Provincial Medical Products Administration, which includes the newly added Changchun, Jilin radiopharmaceutical production center. The approval of this inspection signifies that Andi Ke's Changchun, Jilin radiopharmaceutical production center now meets the requirements for commercial operation, adding another radiopharmaceutical production facility to Andi Ke’s network. Once operational, this new production center will support Andi Ke in expanding its market reach, increasing sales revenue, and further enhancing the nationwide strategic layout of its radiopharmaceutical production network.

Zhitong FinanceJun 15 16:58

Breaking News! This company’s annual report contains false statements and will be subject to other risk warnings | After-Hours Announcement Summary

Sinuo邦 Signs Electrolyte Supply Agreement with CATL, with Estimated Total Purchases of 300,000 Tonnes from 2026 to 2028

cls.cnJun 7 18:13

Dongcheng Pharmaceutical (002675.SZ): Repurchased a cumulative total of 6.3676 million company shares

Gelonghui, June 2 — Dongcheng Pharmaceutical (002675.SZ) announced that, as of May 31, 2026, the company had repurchased 6,367,600 shares through its dedicated securities account for share repurchases via centralized bidding, representing 0.77% of the company's total share capital. The highest transaction price was RMB 15.27 per share, the lowest was RMB 12.15 per share, and the total amount paid was RMB 87,169,513.70 (excluding transaction fees).

Gelonghui FinanceJun 2 16:48

Express News | Dongcheng Pharmaceuticals: Yunkel's Yttrium-90 radiopharmaceutical has commenced customized production.

BreakingsMay 21 12:19

Dongcheng Pharmaceutical (002675.SZ): Subsidiary Intends to Acquire Minority Shareholder Equity in Subsidiary and Accept Directed Capital Increase from Subsidiary

Gelonghui, May 12th ┃ Dongcheng Pharmaceutical (002675.SZ) announced that Yantai Dongcheng Pharmaceutical Group Co., Ltd.'s wholly-owned subsidiary, Nanjing Jiangyuan Andike Positron Research and Development Co., Ltd., will repurchase 34.5454% of the shares held by minority shareholders of its subsidiary, Mido (Yantai) Biotechnology Co., Ltd. (referred to as the "Target Company"), for no more than RMB 452,327,900, corresponding to Yantai Mido's registered capital of RMB 22,376,649. After the completion of this repurchase, the Target Company will increase its registered capital through a targeted capital reserve transfer to Nanjing Jiangyuan Andike Positron Research and Development Co., Ltd., based on its

Gelonghui FinanceMay 12 19:28